TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06865105: A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis

Sponsor: AbbVie · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,245,000

Rescue Site Savings

+$4,795,500

Unlock Full NCT06865105 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06865105 Rescue Dossier →